Skip to main content
Advertisement
Advertisement

LGND

LGND logo

Ligand Pharmaceuticals Inc.

288.05
USD
Sponsored
-0.78
-0.27%
Sep 09, 15:59 UTC -4
Closed
exchange

After-Market

288.06

0.00
0.00%

LGND Earnings Reports

Positive Surprise Ratio

LGND beat 38 of 42 last estimates.

90%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$80.47M
/
$2.40
Implied change from Q2 26 (Revenue/ EPS)
+26.35%
/
+1.27%
Implied change from Q3 25 (Revenue/ EPS)
-7.39%
/
-22.33%

Ligand Pharmaceuticals Inc. earnings per share and revenue

On Aug 06, 2026, LGND reported earnings of 2.37 USD per share (EPS) for Q2 26, beating the estimate of 1.86 USD, resulting in a 27.34% surprise. Revenue reached 63.69 million, compared to an expected 61.98 million, with a 2.76% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 2.40 USD, with revenue projected to reach 80.47 million USD, implying an increase of 1.27% EPS, and increase of 26.35% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
FAQ
For Q2 2026, Ligand Pharmaceuticals Inc. reported EPS of $2.37, beating estimates by 27.34%, and revenue of $63.69M, 2.76% above expectations.
The stock price moved down -0.8%, changed from $302.57 before the earnings release to $300.14 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on -- analysts, Ligand Pharmaceuticals Inc. is expected to report EPS of $2.40 and revenue of $80.47M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement